Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst’s FDA approval and implications

Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst’s FDA approval and implications

ABSTRACTClostridioides difficile infections (CDI) are a leading cause of healthcare-associated infections with a high relapse rate. Current treatment guidelines recommend fidaxomicin as the primary therapy for initial CDI episodes and suggest alternative approaches for recurrent episodes, including...

Full description

Bibliographic Details
Main Authors: Nityanand Jain, Tungki Pratama Umar, Anne-Fleur Fahner, Valdis Gibietis
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Gut Microbes
Subjects:
Clostridioides difficile
fecal microbiota transplant
recurrent
infections
gastroenterology
pharmacovigilance
Online Access:https://www.tandfonline.com/doi/10.1080/19490976.2023.2232137

Internet

https://www.tandfonline.com/doi/10.1080/19490976.2023.2232137

Similar Items